Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-09-28 00:00:00 ET · period of report 2023-09-28 · accession 0001209191-23-050734 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-28 | 2023-09-28 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.87 | +8,000 | 818.5K | +1.0% | +$15.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-28 | P | A | 8,000 | $1.87 | 818,532 | D | — | — | (F1) The Reporting Person purchased all 8,000 shares of common stock in the open market at a price of $1.87 per share. |